High risk multiple myeloma (HRMM) at diagnosis is currently recognized according to the
Revised International Staging System (R-ISS) which was set up in 2015. Since then, new …

Simple Summary The assessment of responses is critical in patients diagnosed with multiple
myeloma. Nowadays, one of the most informative parameters to discriminate responses to …

Background For patients with newly diagnosed multiple myeloma, reaching minimal residual
disease (MRD) negativity after treatment is associated with improved outcomes; however …

PURPOSE The GMMG-CONCEPT trial investigated isatuximab, carfilzomib, lenalidomide,
and dexamethasone (Isa-KRd) in transplant-eligible (TE) and transplant-noneligible (TNE) …

PURPOSE Primary plasma cell leukemia (PCL) is the most aggressive monoclonal
gammopathy. It was formerly characterized by≥ 20% circulating plasma cells (CTCs) until …

PURPOSE Outcomes for patients with newly diagnosed multiple myeloma (NDMM) are
heterogenous, with overall survival (OS) ranging from months to over 10 years. METHODS …

Patients with multiple myeloma (MM) have experienced a markedly improved survival over
the past 25 years, thanks in part to the availability of new drugs [1]. However, a subgroup of …

PURPOSE Although chimeric antigen receptor T therapy (CAR-T) cells are an established
therapy for relapsed/refractory multiple myeloma (RRMM), there are no established models …

Cytogenetic abnormalities (CAs) are known to be the preponderant prognostic factor in
multiple myeloma. Our team has recently developed a prognostic score based on 6 CAs …

Background The prognostic value of additional copies of chromosome 1q (1q
gain/amplification [amp]) in multiple myeloma (MM) remains controversial. In the meantime …